HopeStage
Back to all studies
CompletedNCT00206128

Switching from immediate-release to extended-release quetiapine for schizophrenia

About this titleRead the official source — NCT00206128
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Birmingham and 68 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2004
Recruitment status
Completed
Enrollment listed in the registry
454
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, Canada, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00206128
Official title
Show the full official title

6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Anaheim, United States · Cerritos, United States

65 more locations
  • Garden Grove, United States
  • National City, United States
  • Pasadena, United States
  • San Diego, United States
  • Santa Ana, United States
  • North Miami, United States
  • Atlanta, United States
  • Hoffman Estates, United States
  • New Orleans, United States
  • Jackson, United States
  • Clementon, United States
  • Staten Island, United States
  • Austin, United States
  • Houston, United States
  • Richmond, United States
  • QLD, Australia
  • Burgas, Bulgaria
  • Radnevo, Bulgaria
  • Varna, Bulgaria
  • Vancouver, Canada
  • Aurora, Canada
  • Burlington, Canada
  • Mississauga, Canada
  • Orléans, Canada
  • Toronto, Canada
  • Québec, Canada
  • Sherbrooke, Canada
  • Prince Albert, Canada
  • Põltsamaa, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Helsinki, Finland
  • Mikkeli, Finland
  • Turku, Finland
  • München, Germany
  • Göttingen, Germany
  • Aachen, Germany
  • Jena, Germany
  • Halle, Germany
  • Marburg, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyula, Hungary
  • Nagykálló, Hungary
  • Szeged, Hungary
  • Székesfehérvár, Hungary
  • Bologna, Italy
  • Cagliari, Italy
  • Città di Castello, Italy
  • Ellera Di Corciano, Italy
  • Torino, Italy
  • Bassano del Grappa, Italy
  • Quartu Sant'Elena, Italy
  • Riga, Latvia
  • Sigulda, Latvia
  • Ziegzdrai, Lithuania
  • Klapeda, Lithuania
  • Šiauliai, Lithuania
  • Vilnius, Lithuania
  • Jerez de la Frontera, Spain
  • Alcobendas, Spain
  • Colmenar Viejo, Spain
  • Madrid, Spain
  • Móstoles, Spain
  • Villamartín, Spain

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Seroquel SR.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies